Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
The eligibility criteria provided for this trial appear to be incomplete — the inclusion criteria section is blank, and only one exclusion criterion has been listed.
Based on what is available, here is the plain English summary:
"Who might be able to join this trial:
- The inclusion criteria for this trial have not been listed in the available information. Please confirm eligibility requirements directly with the trial site.
Who may not be able to join:
- People who have a known allergy or sensitivity to any of the ingredients in AJOVY (fremanezumab) may not be able to join.
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yasuhiko Fukuta, PhD, Otsuka Pharmaceutical Co., Ltd.
Phone: +81-6-6943-7722
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety information (Adverse Event); Number of Special Situations; Number of off-Label Use; Incidence of Serious Adverse Event (e.g. resulting in death or life-threatening); Incidence of Non-serious Adverse Events (i.e. all Adverse Events that do not meet the definition of a serious Adverse Event)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.